Company intelligence / Profile preview

Advenchen Laboratories

Moorpark, California, United Statesdnb.com ↗

Ownership: Private
Development stage: Other

Overview

Advenchen Laboratories has a robust pipeline of small molecule kinase inhibitors for oncology indications. Several programs are in late-stage clinical development with multiple ongoing or completed Phase III trials. The company targets a first US NDA submission in 2025 for one of its lead compounds. Its drug candidates have demonstrated strong anti-tumor activity across various cancers.

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Partnerships

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. – co-development/commercialization partner for catequentinib/anlotinib/rivoceranib in China and possibly other Asian markets

Beyond the preview

Go deeper on Advenchen Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advenchen Laboratories.

Explore the full profile